RWTAC: Effects of Dietary Antioxidants to Prevent Cardiovascular Disease

Sponsor
Aeromedical Center, Thessaloniki (Other)
Overall Status
Completed
CT.gov ID
NCT02409537
Collaborator
(none)
37
2
24

Study Details

Study Description

Brief Summary

Background & Aims: The role of red wine in cardiovascular risk prevention has been documented by several epidemiological studies in patients and normocholesterolemic healthy individuals. However, it is unclear whether hypercholesterolemic individuals free of cardiovascular disease would equally benefit from moderate red wine consumption to prevent atherosclerosis and the development of cardiovascular disease.

Methods: Forty (40) healthy volunteers males and females were recruited, divided into 2 age-adjusted groups according to their total cholesterol levels; in asymptomatic hypercholesterolemics (AHC ), and normocholesterolemics (NC ). Total Antioxidant Capacity (TAC ), Lipid profile, Vitamin E, and cardiovascular risk indexes ( LDL /HDL and Vitamin E/TC ) were evaluated in the blood serum of all subjects prior to and 1 month after once daily red wine consumption as well as prior to and after being given a placebo drink following a 1 month wash out period and resveratrol for 1 month after wash out period..

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: red wine
  • Dietary Supplement: resveratrol
  • Other: placebo
Phase 2

Detailed Description

Study design and measurements This study is a cross-over field trial. Participants were asked to consume a specific variety of red wine "tannat" daily in their diet for one month. After a wash-out period of one month, the same participants were asked to consume a placebo drink daily for another month. Quantitative measurements of blood lipids, vitamin E, and Total Antioxidant Capacity before and after consumption of wine and placebo were measured. The study aimed to investigate whether consumption of red wine is associated with any changes in the levels of blood lipids, vitamin E, and Total Antioxidant Capacity and whether such changes - if any -equally occur in hypercholesterolemic individuals.

Participants were advised to abstain from consuming antioxidant supplements, antioxidant-rich foods (including deep-colored fruits and vegetables such as berries, tomatoes, carrots, broccoli, apples and plums, green tea, caffeine and chocolate), caffeine and alcohol 2 weeks prior to the beginning of initial measurements and during the 3-month experimental period. Participants (occasional alcohol drinkers) included in the study received no monetary compensation. According to the U.S. Department of Agriculture 2010 Dietary Guidelines, moderate drinking corresponds to one drink per day for women and two for men14. Consequently, female subjects were given 5 bottles of red wine for 1 month (1 glass per day), and male subjects were given 10 bottles (2 glasses/per day) and instructed to report any side effects or failure to participate. The single grape variety of Tannat, from a location in Northern Greece, was selected among several varieties of red wine for its content in phenolic compounds and high antioxidant gradient when tested in vitro. Participants were encouraged to not alter their dietary habits or physical activity level during the study. To verify their compliance with the instructions provided, we interviewed them before and after the experiment, and we also measured the quantity of wine used. One day prior to the beginning of the intervention, participants underwent physical and routine biochemical examinations and completed two questionnaires, one related to their health status and the other to their characteristics. To confirm protocol adherence, a team of colleagues contacted the participants by telephone every 2nd day and they visited the clinic to obtain 1 bottle of wine and answered a questionnaire regarding their adherence with the protocol requirements.

For each subject, measurements of serum TAC and vitamin E were performed pre and post 1 month of red wine ingestion and pre and post placebo drink ingestion after a 1 month wash out period. For vitamin E measurements, fasting subjects were requested to abstain from alcohol for 24 hours prior to the blood draw. Serum levels of Total Cholesterol (TC), triglycerides (TG), HDL-cholesterol, and LDL-cholesterol were also measured by enzymatic methods. For serum HDL-cholesterol levels, fasting blood was collected in tubes with a clot activator and was determined enzymatically.

For the assessment of cardiovascular risk, pre and post red wine consumption ratios (LDL/HDL-cholesterol and vitamin E/TC) were calculated. TG/HDL-cholesterol, a marker for insulin resistance, was also proposed as a surrogate marker of cardiovascular risk assessment. TC/HDL and LDL/HDL are also considered to be strong predictors of the degree of clinical benefit from lipid-lowering interventions.

Study Design

Study Type:
Interventional
Actual Enrollment :
37 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Cardiovascular Risk and Benefits From Antioxidant Dietary Intervention With Red Wine in Asymptomatic Hypercholesterolemics
Study Start Date :
Mar 1, 2013
Actual Primary Completion Date :
Mar 1, 2014
Actual Study Completion Date :
Mar 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: non cholesterolemic individuals

Individuals with normal cholesterol levels will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.

Dietary Supplement: red wine
the individuals were given red wine to consume for 1 month then a wash out period of 1 month

Dietary Supplement: resveratrol
the individuals were given resveratrol for 1 month and then 1 month wash out period

Other: placebo
the individuals were given placebo for 1 month

Active Comparator: Asymptomatic Hypercholesterolemics

individuals with high levels of cholesterol with no cardiovascular disease Those individuals will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.

Dietary Supplement: red wine
the individuals were given red wine to consume for 1 month then a wash out period of 1 month

Dietary Supplement: resveratrol
the individuals were given resveratrol for 1 month and then 1 month wash out period

Other: placebo
the individuals were given placebo for 1 month

Outcome Measures

Primary Outcome Measures

  1. Total antioxidant activity (TAC) [6 months]

    TAC was measured after 1 month of red wine consumption, resveratrol and placebo and wash out periods in between

  2. Vitamin E [6 months]

    Vitamin E was measured after 1 month of red wine consumption, resveratrol and placebo and wash out periods in between

  3. Total Cholesterol [6 months]

    Total cholesterol was measured after 1 month of red wine consumption, resveratrol and placebo and wash out periods in between

  4. LDL/HDL [6 months]

    The ratio LDL/HDL was measured after 1 month of red wine consumption, resveratrol and placebo and wash out periods in between

Secondary Outcome Measures

  1. Vitamin E/ Total Cholesterol [6 months]

    The ratio Vitamin E/ Total Cholesterol was measured after 1 month of red wine consumption, resveratrol and placebo and wash out periods in between

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy volunteers with normal or high cholesterol level with no cardiovascular disease
Exclusion Criteria:
  • documented dyslipidemia (abnormal level of fat or cholesterol (very high or very low),

  • chronic liver disease, malnutrition, neoplastic or acute infectious diseases,

  • habitual use of vitamin supplements.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Aeromedical Center, Thessaloniki

Investigators

  • Study Director: Konstantinos Adamopoulos, PhD, Aristotle University of Thessaloniki, School of engineering, Faculty of Chemical Engineering, Division of technology laboratory of food and process engineering,
  • Principal Investigator: Christina Apostolidou, MS, Aristotle University of Thessaloniki, School of engineering, Faculty of Chemical Engineering, Division of technology laboratory of food and process engineering,

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christina Apostolidou, Aristotle University of Thessaloniki, School of engineering, Faculty of Chemical Engineering, Division of technology laboratory of food and process engineering, Aeromedical Center, Thessaloniki
ClinicalTrials.gov Identifier:
NCT02409537
Other Study ID Numbers:
  • 0011
First Posted:
Apr 7, 2015
Last Update Posted:
Apr 7, 2015
Last Verified:
Apr 1, 2015
Keywords provided by Christina Apostolidou, Aristotle University of Thessaloniki, School of engineering, Faculty of Chemical Engineering, Division of technology laboratory of food and process engineering, Aeromedical Center, Thessaloniki
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2015